Oral icotrokinra sustained scalp, genital, and hand/foot psoriasis clearance through week 112 in ICONIC-TOTAL, with no new safety signals.
|Articles|July 1, 2006
Eye on Washington
Advertisement
July begins with a bang in the nation's capital-a literal one. Tourists oohhh and aahhh over the magnificent fireworks display that arcs the night sky of the National Mall on Independence Day. Members of Congress, on the other hand, celebrate at home, where they meet and greet constituents on parade routes and around barbecue pits.
Advertisement
Related to this article
A 16-month-old with recurrent otitis media developed a spreading unilateral rash on her hip and thigh during antibiotic treatment. PCR testing confirmed herpes zoster, an uncommon diagnosis in young, vaccinated children.
Upadacitinib showed continued facial and body repigmentation in NSV through week 76, with numerically higher responses when combined with NB-UVB.
Can you guess the diagnosis?
The approval is based on BRAVE-AA-PEDS, in which 42% of adolescents receiving baricitinib 4 mg achieved at least 80% scalp hair coverage at week 36 vs 5% with placebo.
Higher preconception maternal and paternal vitamin B12 was tied to fewer birth defects in a Shanghai cohort of 3032 couples.
The FDA accepted the dersimelagon NDA with priority review for EPP and XLP; a decision on the oral MC1R agonist is expected by February 2027.
Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Type 1 diabetes update: Immune therapy, screening, and new technology
2
Adolescent suicidal ideation trend reversed around 2009, analysis finds
3
What pediatricians should know about the 2026-27 AAP vaccine schedule
4
Constipation may be an overlooked driver of urinary symptoms in children
5